Avalyn Pharma (NASDAQ:AVLN) Sets New 1-Year High – What’s Next?

Avalyn Pharma Inc. (NASDAQ:AVLN) shares hit a new 52-week high on Monday . The company traded as high as $32.36 and last traded at $31.72, with a volume of 77055 shares changing hands. The stock had previously closed at $31.45.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on AVLN shares. Morgan Stanley initiated coverage on shares of Avalyn Pharma in a report on Tuesday, May 26th. They issued an “overweight” rating and a $53.00 price target for the company. Zacks Research raised shares of Avalyn Pharma to a “hold” rating in a research report on Wednesday, May 27th. Wall Street Zen raised shares of Avalyn Pharma to a “hold” rating in a research note on Saturday, May 9th. Evercore began coverage on Avalyn Pharma in a report on Tuesday, May 26th. They set an “outperform” rating and a $51.00 target price for the company. Finally, Guggenheim started coverage on Avalyn Pharma in a research note on Monday, May 25th. They issued a “buy” rating and a $80.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $59.00.

Avalyn Pharma Stock Performance

Avalyn Pharma (NASDAQ:AVLN) last announced its quarterly earnings data on Wednesday, June 3rd. The company reported ($21.83) EPS for the quarter, missing analysts’ consensus estimates of ($16.38) by ($5.45).

Insider Activity

In related news, major shareholder Sr One Capital Management, Llc acquired 555,555 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was bought at an average price of $18.00 per share, for a total transaction of $9,999,990.00. Following the acquisition, the insider directly owned 2,186,562 shares of the company’s stock, valued at approximately $39,358,116. The trade was a 34.06% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jill Carroll bought 277,778 shares of the stock in a transaction that occurred on Friday, May 1st. The stock was bought at an average cost of $18.00 per share, for a total transaction of $5,000,004.00. Following the transaction, the director owned 2,186,562 shares of the company’s stock, valued at $39,358,116. The trade was a 14.55% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

Avalyn Pharma Company Profile

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.